DOCSLIB.ORG

抗微生物薬略語一覧表 （Abbreviations of Antimicrobial Agents） （日本化学療法学会制定）

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
抗微生物薬略語一覧表 （Abbreviations of Antimicrobial Agents） （日本化学療法学会制定） 抗微生物薬略語一覧表 （Abbreviations of Antimicrobial Agents） （日本化学療法学会制定） 略 語 一般名（慣用名） 開発番号 略 語 一般名（慣用名） 開発番号 BLs ● β-ラクタム系 CEC cephacetrile （β-lactams） CEPR cephapirin PCs ペニシリン系 CER cephaloridine （penicillins） CET cephalothin ABPC ampicillin CEZ cefazolin ACPC ciclacillin CFCL cefclidin E1040 AMPC amoxicillin CFDC cefiderocol S-649266 APPC apalcillin PC-904 CFLP cefluprenam E1077 ASPC aspoxicillin TA-058 CFPM cefepime BMY-28142 BAPC bacampicillin CFS cefsulodin SCE-129 CBPC carbenicillin CFSL cefoselis FK037 CFPC carfecillin CMD cefamandole CIPC carindacillin CMX cefmenoxime SCE-1365 DMPPC methicillin CPIZ cefpimizole AC-1370 IPABPC hetacillin CPM cefpiramide SM-1652 LAPC lenampicillin KBT-1585 CPR cefpirome HR-810 MCIPC cloxacillin CPZ cefoperazone T-1551 MDIPC dicloxacillin CTM cefotiam SCE-963 MFIPC flucloxacillin CTRX ceftriaxone Ro13-9904 MPC mecillinam CTX cefotaxime MPIPC oxacillin CTZ ceftezole MZPC mezlocillin CXM cefuroxime NFPC nafcillin CZON cefuzonam L-015 PCG benzylpenicillin CZOP cefozopran SCE-2787 （penicillin G） CZX ceftizoxime PCV phenoxymethyl penicillin SBT/CPZ sulbactam/cefoperazone （penicillin V） TAZ/CTLZ tazobactam/ceftolozane MK-7625A PEPC phenethicillin （経口用） PIPC piperacillin CCL cefaclor PMPC pivmecillinam CDTR-PI cefditoren pivoxil ME-1207 PPPC propicillin CDX cefadroxil BL-S578 PVPC pivampicillin CED cefradine SBPC sulbenicillin CEG cephaloglycin SBTPC sultamicillin CEMT-PI cefetamet pivoxil Ro15-8075 TAPC talampicillin CETB ceftibuten 7432-S TIPC ticarcillin CEX cephalexin ABPC/ CFDN cefdinir FK482 MCIPC ampicillin/cloxacillin CFIX cefixime FK027 CVA/ CFPN-PI cefcapene pivoxil S-1108 AMPC clavulanic acid/amoxicillin BRL25000 CFPZ cefprozil BMY-28100 CVA/ CFT cefatrizine TIPC clavulanic acid/ticarcillin BRL28500 CFTM-PI cefteram pivoxil T-2588 SBT/ CPDX-PR cefpodoxime proxetil CS-807 ABPC sulbactam/ampicillin CTM-HE cefotiam hexetil SCE-2174 TAZ/PIPC tazobactam/piperacillin YP-14 CXD cefroxadine CGP-9000 セフェム系（cephems） CXM-AX cefuroxime axetil SN407 CEPs セファロスポリン系 CZX-AP ceftizoxime alapivoxil AS-924 （cephalosporins） セファマイシン系 （注射用） （cephamycins） CAZ ceftazidime SN401 CBPZ cefbuperazone T-1982 CDZM cefodizime THR-221 CFX cefoxitin 系統内は略語のアルファベット順に（ただし合剤はそれぞれの系統内末尾に略語のアルファベット順で）記載されています。 日本化学療法学会雑誌 Vol. 69 No. 5 413 略 語 一般名（慣用名） 開発番号 略 語 一般名（慣用名） 開発番号 CMNX cefminox MT-141 SPCM spectinomycin CMZ cefmetazole CS-1170 TOB tobramycin CTT cefotetan YM09330 MLs ●マクロライド系 オキサセフェム系 （macrolides） （oxacephems） AZM azithromycin CP-62, 993 FMOX flomoxef 6315-S CAM clarithromycin TE-031 LMOX latamoxef 6059-S EM erythromycin ペネム系 FDX fidaxomicin （penems） JM josamycin FRPM faropenem SY5555 LM kitasamycin RIPM-AC ritipenem acoxil FC/TA-891 （leucomycin） カルバペネム系 MDM midecamycin （carbapenems） OL oleandomycin BIPM biapenem L-627 RKM rokitamycin TMS-19-Q DRPM doripenem S-4661 RXM roxithromycin RU28965 MEPM meropenem SM-7338 SPM spiramycin TBPM-PI tebipenem pivoxil ME1211 LCMs ●リンコマイシン系 IPM/CS imipenem/cilastatin MK0787/ （lincomycins） MK0791 CLDM clindamycin PAPM/BP panipenem/betamipron CS-976 LCM lincomycin REL/IPM/ relebactam/imipenem/ MK-7655A KLs ●ケトライド系 CS cilastatin （ketolides） カルバセフェム系 TEL telithromycin HMR 3647 （carbacephems） FKLs ●フルオロケトライド系 LCBF loracarbef KT3777 （fluoroketolides） モノバクタム系 SOL solithromycin T-4288 （monobactams） SGs ●ストレプトグラミン系 AZT aztreonam SQ26, 776 （streptogramins） CRMN carumonam AMA-1080 QPR/DPR quinupristin/dalfopristin β-ラクタマーゼ阻害薬 QLs ●キノロン系 （β-lactamase inhibitors） （quinolones） CVA clavulanic acid BLFX balofloxacin Q-35 REL relebactam CINX cinoxacin SBT sulbactam CPFX ciprofloxacin BAYo9867 TAZ tazobactam ENX enoxacin AT-2266 AGs ●アミノグリコシド系 FLRX fleroxacin AM-833 （aminoglycosides） GFLX gatifloxacin AM-1155 ABK arbekacin HBK GPFX grepafloxacin OPC-17116 AKM bekanamycin GRNX garenoxacin mesilate hydrate T-3811ME AMK amikacin LFLX lomefloxacin NY-198 ASTM astromicin KW-1070 LSFX lascufloxacin AM-1977 DKB dibekacin LVFX levofloxacin DR-3355 FRM fradiomycin MFLX moxifloxacin BAY12-8039 （neomycin） MLX miloxacin AB-206 GM gentamicin NA nalidixic acid ISP isepamicin HAPA-B NDFX nadifloxacin OPC-7251 KM kanamycin NFLX norfloxacin AM-715 LVDM lividomycin OFLX ofloxacin DL-8280 MCR micronomicin OZNX ozenoxacin T-3912 NTL netilmicin PA piromidic acid PRM paromomycin PPA pipemidic acid RSM ribostamycin PUFX prulifloxacin NM441 SISO sisomicin PZFX pazufloxacin T-3761 SM streptomycin PZFX-ME pazufloxacin mesilate T-3762 414 日本化学療法学会雑誌 Vol. 69 No. 5 略 語 一般名（慣用名） 開発番号 略 語 一般名（慣用名） 開発番号 SPFX sparfloxacin AT-4140 ●抗結核薬 STFX sitafloxacin DU-6859 （anti-mycobacterial agents） TFLX tosufloxacin T-3262 CPRM capreomycin TMFX temafloxacin TA-167 CS cycloserine TCs ●テトラサイクリン系 EB ethambutol （tetracyclines） ETH ethionamide 1314 TH CTC chlortetracycline EVM enviomycin DMCTC demethylchlortetracycline （tuberactinomycin） DOXY doxycycline INH isoniazid MINO minocycline PAS p-aminosalicylic acid MTC methacycline PTH prothionamide 1321 TH OTC oxytetracycline PZA pyrazinamide TC tetracycline RBT rifabutin CPs ●クロラムフェニコール系 RFP rifampicin （chloramphenicols） THZ thiazolidomycin CP chloramphenicol VM viomycin TP thiamphenicol ●抗真菌薬 OZs ●オキサゾリジノン系 （antifungal agents） （oxazolidinones） AMPH-B amphotericin B LZD linezolid CPFG caspofungin acetate TZD tedizolid EFCZ efinaconazole PLs ●ポリペプチド系 F-FLCZ fosfluconazole UK-292, 663 （polypeptides） FLCZ fluconazole UK-49858 BC bacitracin Fosravuconazole L-Lysine F-RVCZ CL colistin Ethanolate PL-B polymyxin B GRF griseofulvin GPs ●グリコペプチド系 ISCZ isavuconazole （glycopeptides） ITCZ itraconazole TEIC teicoplanin KCZ ketoconazole VCM vancomycin L-AMB liposomal amphotericin B SM-26000 ●リポペプチド系 MCFG micafungin FK463 （lipopeptides） MCZ miconazole DAP daptomycin NYS nystatin ●グリシルサイクリン系 PMR pimaricin （glycylcyclines） PNT pentamycin TGC tigecycline PSCZ posaconazole MK-5592 ●その他の抗菌薬 RVCZ ravuconazole （ miscellaneous antibacterial TRM trichomycin agents） VR variotin CMRM coumermycin VRCZ voriconazole UK-109, 496 CRM carbomycin 5-FC flucytosine EDC enramycin ●抗ウイルス薬 FA fusidic acid （antiviral agents） FOM fosfomycin AMNV amenamevir ASP2151 KSM kasugamycin MKM mikamycin MNZ metronidazole MUP mupirocin NB novobiocin NF nitrofurazone RCT ristocetin sulfamethoxazole- ST trimethoprim 日本化学療法学会雑誌 Vol. 69 No. 5 415.
Load more

Recommended publications
  • WO 2018/005606 Al 04 January 2018 (04.01.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/005606 Al 04 January 2018 (04.01.2018) W !P O PCT (51) International Patent Classification: KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, A61K 38/43 (2006.01) A61K 47/36 (2006.01) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, A61K 38/50 (2006.01) A61K 9/S0 (2006.01) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, A61K 33/44 {2006.01) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (21) International Application Number: PCT/US20 17/039672 (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (22) International Filing Date: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 28 June 2017 (28.06.2017) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (25) Filing Language: English TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (26) Publication Langi English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (30) Priority Data: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 62/355,599 28 June 2016 (28.06.2016) US KM, ML, MR, NE, SN, TD, TG).
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Ceftaroline in the Management of Complicated Skin and Soft Tissue Infections and Community Acquired Pneumonia
    Journal name: Therapeutics and Clinical Risk Management Article Designation: Review Year: 2015 Volume: 11 Therapeutics and Clinical Risk Management Dovepress Running head verso: Mpenge and MacGowan Running head recto: Ceftaroline in the management of cSSTI and CAP open access to scientific and medical research DOI: http://dx.doi.org/10.2147/TCRM.S75412 Open Access Full Text Article REVIEW Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia Mbiye A Mpenge¹ Abstract: Ceftaroline is a new parenteral cephalosporin approved by the European Medicines Alasdair P MacGowan² Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of com- plicated skin and soft tissue infections (cSSTIs) including those due to methicillin-resistant ¹Department of Medical Microbiology, University Hospitals Bristol NHS Staphylococcus aureus (MRSA), and community-acquired pneumonia (CAP). Ceftaroline has Trust, Bristol Royal Infirmary, Bristol, broad-spectrum activity against gram-positive and gram-negative bacteria and exerts its bacteri- England; ²Department of Medical Microbiology, North Bristol NHS cidal effects by binding to penicillin-binding proteins (PBPs), resulting in inhibition of bacterial Trust, Southmead Hospital, Bristol, cell wall synthesis. It binds to PBP 2a of MRSA with high affinity and also binds to all six PBPs England in Streptococcus pneumoniae. In in vitro studies, ceftaroline demonstrated potent activity against Staphylococcus aureus (including MRSA and vancomycin-intermediate isolates), Streptococ- For personal use only. cus pneumoniae (including multidrug resistant isolates), Haemophilus influenzae, Moraxella catarrhalis, and many common gram-negative pathogens, excluding extended spectrum beta- lactamase (ESBL)-producing Enterobacteriaceae and Pseudomonas aeruginosa. In Phase II and Phase III clinical trials, ceftaroline was noninferior to its comparator agents and demonstrated high clinical cure rates in the treatment of cSSTIs and CAP.
    [Show full text]
  • Guidelines on Urinary and Male Genital Tract Infections
    European Association of Urology GUIDELINES ON URINARY AND MALE GENITAL TRACT INFECTIONS K.G. Naber, B. Bergman, M.C. Bishop, T.E. Bjerklund Johansen, H. Botto, B. Lobel, F. Jimenez Cruz, F.P. Selvaggi TABLE OF CONTENTS PAGE 1. INTRODUCTION 5 1.1 Classification 5 1.2 References 6 2. UNCOMPLICATED UTIS IN ADULTS 7 2.1 Summary 7 2.2 Background 8 2.3 Definition 8 2.4 Aetiological spectrum 9 2.5 Acute uncomplicated cystitis in pre-menopausal, non-pregnant women 9 2.5.1 Diagnosis 9 2.5.2 Treatment 10 2.5.3 Post-treatment follow-up 11 2.6 Acute uncomplicated pyelonephritis in pre-menopausal, non-pregnant women 11 2.6.1 Diagnosis 11 2.6.2 Treatment 12 2.6.3 Post-treatment follow-up 12 2.7 Recurrent (uncomplicated) UTIs in women 13 2.7.1 Background 13 2.7.2 Prophylactic antimicrobial regimens 13 2.7.3 Alternative prophylactic methods 14 2.8 UTIs in pregnancy 14 2.8.1 Epidemiology 14 2.8.2 Asymptomatic bacteriuria 15 2.8.3 Acute cystitis during pregnancy 15 2.8.4 Acute pyelonephritis during pregnancy 15 2.9 UTIs in post-menopausal women 15 2.10 Acute uncomplicated UTIs in young men 16 2.10.1 Pathogenesis and risk factors 16 2.10.2 Diagnosis 16 2.10.3 Treatment 16 2.11 References 16 3. UTIs IN CHILDREN 20 3.1 Summary 20 3.2 Background 20 3.3 Aetiology 20 3.4 Pathogenesis 20 3.5 Signs and symptoms 21 3.5.1 New-borns 21 3.5.2 Children < 6 months of age 21 3.5.3 Pre-school children (2-6 years of age) 21 3.5.4 School-children and adolescents 21 3.5.5 Severity of a UTI 21 3.5.6 Severe UTIs 21 3.5.7 Simple UTIs 21 3.5.8 Epididymo orchitis 22 3.6 Diagnosis 22 3.6.1 Physical examination 22 3.6.2 Laboratory tests 22 3.6.3 Imaging of the urinary tract 23 3.7 Schedule of investigation 24 3.8 Treatment 24 3.8.1 Severe UTIs 25 3.8.2 Simple UTIs 25 3.9 References 26 4.
    [Show full text]
  • CP-70429, a New Penem Antibiotic
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1993, P. 1547-1551 Vol. 37, No. 7 0066-4804/93/071547-05$02.00/0 Copyright © 1993, American Society for Microbiology In Vitro Antibacterial Activity and ,-Lactamase Stability of CP-70,429, a New Penem Antibiotic MASASHI MINAMIMURA, YUMI TANIYAMA, EIKO INOUE,* AND SUSUMU MITSUHASHI Episome Institute, 2220 Kogure, Fujimi-mura, Seta-gun, Gunma, Japan Received 14 January 1993/Accepted 15 April 1993 In in vitro susceptibility tests, the new penem CP-70,429 showed potent antibacterial activity against gram-positive and gram-negative bacteria except Pseudomonas aeruginosa and Xanthomonas maltophilia. CP-70,429 was stable to various types of 13-lactamases except for the enzyme from X. maltophilia and was 16- to 128-fold more active than the other compounds against 13-lactamase-producing strains of Enterobacter cloacae and Citrobacterfreundii. In the past several years, many 1-lactam antibiotics with cus aureus, like the other agents against which CP-70,429 broad antibacterial activities have undergone clinical trials. was compared. CP-70,429 showed potent activity against The penem antibiotics FCE22101 and SY5555 have broad streptococci, as did the other compounds tested. Against antimicrobial spectra and high levels of stability to ,B-lacta- Enterococcus faecalis, CP-70,429 was 4- to 16-fold more mases (4, 9). The in vitro activity of CP-65,207 was previ- active than the cephems tested, on the basis of the MIC90s. ously reported by Gootz et al. (3); CP-65,207 is a mixture of CP-70,429 was the most active compound against Esche- stereoisomers of the optically pure CP-70,429.
    [Show full text]
  • Of Cephalosporins. Cefuzonam (CZON, Lederle Japan, Ltd
    1346 THE JOURNAL OF ANTIBIOTICS AUG. 1992 STRUCTURE-BINDING RELATIONSHIP AND BINDING SITES OF CEPHALOSPORINS IN HUMAN SERUM ALBUMIN Shuichi Tawara*, Satoru Matsumoto1, Yoshimi Matsumoto1, Toshiaki Kamimura^* and Sachiko GoTOn f New Drug Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., 2-1-6 Kashima, Yodogawa-ku, Osaka 532, Japan tjDepartment of Microbiology, Toho University School of Medicine, 5-21-16 Ohmori Nishi, Ohta-ku, Tokyo 143, Japan (Received for publication January 29, 1992) The binding of some cephalosporins to human serum albumin (HSA) was studied by an ultra filtration technique. Changes in C-3 side chain resulted in marked changes in the binding to HSA,but changes in C-7 side chain did not. Cephalosporins were classified into three groups by C-3 side chain: (i) Cationic side chain with low affinity for HSA;(ii) anionic side chain with high affinity for HSA; (iii) non ionized side chain, in which binding to HSAwas dependent on lipophilicity. These findings suggest that electrostatic and hydrophobic forces play a role in the binding affinity of cephalosporins for HSA. The binding of cephalosporins with high HSAaffinity was displaced significantly by warfarin but not by phenylbutazone, L-tryptophan, or diazepam. The interaction of the cephalosporins with high affinity for HSAwith chemically modified HSAwas investigated to clarify the amino acid residues of HSAinvolved in the cephalosporin binding sites. The binding of the cephalosporins decreased remarkably with the modification of the tyrosine residues. These results suggest that the binding site of cephalosporins is located in the vicinity of warfarin binding site rather than benzodiazepine binding site and that tyrosine residues are involved in the cephalosporin binding site.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya Et Al
    US 2006.0024.365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya et al. (43) Pub. Date: Feb. 2, 2006 (54) NOVEL DOSAGE FORM (30) Foreign Application Priority Data (76) Inventors: Navin Vaya, Gujarat (IN); Rajesh Aug. 5, 2002 (IN)................................. 699/MUM/2002 Singh Karan, Gujarat (IN); Sunil Aug. 5, 2002 (IN). ... 697/MUM/2002 Sadanand, Gujarat (IN); Vinod Kumar Jan. 22, 2003 (IN)................................... 80/MUM/2003 Gupta, Gujarat (IN) Jan. 22, 2003 (IN)................................... 82/MUM/2003 Correspondence Address: Publication Classification HEDMAN & COSTIGAN P.C. (51) Int. Cl. 1185 AVENUE OF THE AMERICAS A6IK 9/22 (2006.01) NEW YORK, NY 10036 (US) (52) U.S. Cl. .............................................................. 424/468 (22) Filed: May 19, 2005 A dosage form comprising of a high dose, high Solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of Related U.S. Application Data immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of (63) Continuation-in-part of application No. 10/630,446, modified release active ingredient per unit is from 500 mg to filed on Jul. 29, 2003. 1500 mg, a process for preparing the dosage form. Patent Application Publication Feb. 2, 2006 Sheet 1 of 10 US 2006/0024.365A1 FIGURE 1 FIGURE 2 FIGURE 3 Patent Application Publication Feb. 2, 2006 Sheet 2 of 10 US 2006/0024.365A1 FIGURE 4 (a) 7 FIGURE 4 (b) Patent Application Publication Feb. 2, 2006 Sheet 3 of 10 US 2006/0024.365 A1 FIGURE 5 100 ov -- 60 40 20 C 2 4.
    [Show full text]
  • Empiric Treatment with Antibiotic Combination Therapy Compared with Monotherapy for Adult Patients with Septic Shock of Unknown
    REPORT 2020 SYSTEMATIC REVIEW: Empiric treatment with antibiotic combination therapy compared with monotherapy for adult patients with septic shock of unknown pathogen and origin Utgitt av Norwegian Institute of Public Health Division for Health Services Title Empiric treatment with antibiotic combination therapy compared with monotherapy for adult patients with septic shock of unknown pathogen and origin: a systematic review Norwegian title Hva er effekten av empirisk kombinasjonsbehandling med antibiotika sammen- lignet med monoterapi for voksne pasienter med septisk sjokk forårsaket av ukjent patogen og ukjent opprinnelse: en systematisk oversikt Responsible Camilla Stoltenberg, Director General Authors Jan PW Himmels, project leader, seniorrådgiver, Norwegian Institute of Public Health Gunn Elisabeth Vist, seniorforsker, Norwegian Institute of Public Health Liv Giske, seniorforsker, Norwegian Institute of Public Health Eva Helene Arentz-Hansen, seniorforsker, Norwegian Institute of Public Health Gyri Hval, bibliotekar, Norwegian Institute of Public Health ISBN 978-82-8406-084-2 Project number RL035 Type of report Systematic Review No. of pages 26 (32 inklusiv vedlegg) Client Helsedirektoratet Subject Septic shock, antibiotic dual treatment, antibiotic monotherapy, antimicrobi- heading(MeSH) otic ressistance (AMR) Citation Himmels JPW, Vist GE, Giske L, Arentz-Hansen EH, Hval G. Empiric treatment with antibiotic combination therapy compared with monotherapy for adult patients with septic shock of unknown pathogen and origin: a systematic
    [Show full text]
  • Consideration of Antibacterial Medicines As Part Of
    Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1.
    [Show full text]
  • WO 2010/025328 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 4 March 2010 (04.03.2010) WO 2010/025328 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US2009/055306 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 28 August 2009 (28.08.2009) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/092,497 28 August 2008 (28.08.2008) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): FOR¬ GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, EST LABORATORIES HOLDINGS LIMITED [IE/ ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, —]; 18 Parliament Street, Milner House, Hamilton, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, Bermuda HM12 (BM).
    [Show full text]
  • Computational Antibiotics Book
    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
    [Show full text]